Introduction: Commonly used clinical tests for posterior cruciate ligament (PCL) rupture 34 detection exhibit several limitations, thus requiring more precise clinical PCL tests. The 35 lateral-anterior drawer (LAD) test has been proposed as a manually applied testing alternative 36
F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y 3
STRENGTH AND LIMITATIONS OF THIS STUDY 59
Strength: 60 -Timely and accurate clinical PCL rupture detection is of paramount importance in 61 order to protect affected patients from long-term afflictions such as premature 62 cartilage or meniscal degeneration. 63 -The LAD test could be a useful clinical PCL test that overcomes the limitations of 64 commonly used PCL tests such as the Posterior Sag Sign and Posterior Drawer Test. 65 -The present study is adequately powered to detect clinically significant levels of LAD 66 test inter-and intra-rater reliability. Moreover, this is the first study to provide 67 sensitivity and specificity data as well as positive and negative likelihood ratios of the 68 LAD test. Furthermore, it is the first study to provide preliminary data on whether 69 experience with the LAD test influences concurrent validity. 70 -The study design takes account of measurement bias and ascertainment bias. 1 Most likely, this was due to 78 poor understanding of the ligaments' complexity, its definite role, 2 and an underestimation of 79 PCL rupture prevalence and incidence. Since the PCL is nowadays considered an essential 80 knee stabilizer, the importance of sufficient diagnostic testing comes to the fore.
2,3 However, 81
clinical PCL rupture detection can be delayed or even missed, often due to mild symptoms in 82 the acute stage. 4 In the clinical setting, three tests are commonly used for examining PCL 83 integrity: (1) the Posterior Sag Sign (or Gravity Sign), (2) the Posterior Drawer Test, and (3) 84 the Quadriceps Active Test.
2 However, these tests are often unable to sufficiently detect PCL 85 ruptures 4-6 necessitating more precise clinical PCL tests.
6,12
86
The Lateral-Anterior Drawer (LAD) test is an adaptation of the Lateral Shear Test, 87 which was developed by Dr. James Cyriax
12
. The LAD test has been introduced as a manually 88 applied testing alternative 7,12 which attempts to resolve the weaknesses of the above clinical 89 testing procedures. This test examines the knee while positioned in 90° of flexion, with the 90 patient lying supine, so the PCL is aligned nearly perpendicular to the tibial plateau. 8 In this 91 knee position, the PCL is enabled to restrict lateral movement of the tibia versus the femur.
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With respect to the intercondylar eminence, the LAD testing force is applied from medial and 93 slightly posterior (also recognized as medial-posterior) to lateral and slightly anterior (also 94 recognized as lateral-anterior) in the direction of Gerdy's tubercle 7 
(Figure 1). 95
Both construct and concurrent validity of the LAD test as a valid measure for identifying PCL 96 integrity have recently been established in a cadaveric study. 12 However, whether the LAD 97 test indeed sufficiently detects PCL ruptures in vivo, and whether it shows clinically 98 significant levels of intra-and inter-rater reliability remains to be examined. Furthermore, 99 concurrent validity of the LAD test compared to magnetic resonance imaging (MRI) has not 100 yet been evaluated. Therefore, the main objective of the present study is to investigate if the 101 F o r p e e r r e v i e w o n l y 5 LAD test reveals a clinically significant level of intra-and inter-rater reliability when applied 102 in vivo. Additionally, this study aims to evaluate the concurrent validity of the LAD test. 103 Therefore, test outcomes will be compared to MRI, which is considered the current reference 104 standard in PCL rupture diagnostics, because it shows high correlation with arthroscopic 105 findings. [13] [14] [15] [16] [17] [18] Moreover, this study aims to investigate whether differences in LAD test 106 accuracy are subject to the investigator's experience with the LAD test. 107
108
METHODS AND ANALYSIS 109
Study design 110
This evaluation of validity and intra/inter-rater reliability is a prospective, single-blinded 111 cross-sectional cohort study. 112
113
Sample size calculation 114
Donner and Rotondi
19 supply the sample size requirements that achieve a pre-specified 115 expected lower limit for the 95% confidence interval about the intraclass kappa statistic κ for 116 the case of multiple raters and a binary outcome variable. The estimated prevalence of 117 ruptured PCLs is expected to be 25%. Based on this estimation and on a hypothesized lower 118 limit for the 95% confidence interval of a kappa value of 0.6, at least 55 knees need to be 119 included in order to determine the presence of a clinically significant inter-rater agreement. 120 Therefore, 15 PCL-deficient knees and 45 healthy knees will be included for testing, resulting 121 in a total sample size of 30 subjects. Correspondingly, 15 patients presenting with an MRI 122 confirmed acute or chronic unilateral PCL rupture and 15 subjects with no prior knee injury in 123 their medical history will be included in the study. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   6 Subject recruitment and inclusion and exclusion criteria 127
Patients will be recruited from the trauma hospital Unfallkrankenhaus Klagenfurt (Austria) by 128 one of the participating medical doctors according to pre-defined inclusion and exclusion 129 criteria. Eligible patients need to present with an acute or chronic unilateral PCL rupture as 130 confirmed by MRI scan interpreted by an independent radiologist prior to inclusion. The 131 healthy age-and gender-matched control group will be recruited from the staff of the Speising 132
Orthopaedic Hospital (Vienna, Austria). The complete study procedure is depicted in Figure 2  133 and will be discussed in detail in the subsequent sections. In order to take part in this study, 134 participants must fulfill the following inclusion criteria: 135
(1) Age >18 years; 136 (2) Acute* or chronic* unilateral PCL rupture (confirmed by MRI scan prior to study); 137 (3) Males and females; 138 (4) Signed written informed consent; 139 (5) First-time PCL rupture. 140 * In this context, acute means <3 months since the initial injury/traumatic incidence; 141 chronic means >3 months must have passed since the injury/traumatic incidence. 142
Subjects that fulfill at least one of the following criteria are not allowed to participate in this 143 study: 144
(1) Persons not capable of understanding spoken and/or written German; 145 (2) Presence of a total knee arthroplasty; 146 (3) Previous ACL and/or PCL operations at one or both knees; 147 (4) Stroke or other neurological conditions that impair lower extremity function (e.g. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Preparation procedure 158
The names of eligible patients will be recorded on a recruiting list at the study center at 159 Unfallkrankenhaus Klagenfurt. Subsequently, those patients will be called by an independent 160 study assistant who will inform them about the study and ask if they are interested to 161 participate. Those interested will be marked on the list. At the end of patient recruiting, the 162 study assistant will enroll gender-and age-matched healthy subjects from the staff of the 163 Speising Orthopaedic Hospital in Vienna. The study assistant will schedule patients and 164 healthy subjects for examination on an extended weekend. At the time of appointment, the 165 patient will be (1) received by the independent study assistant, who (2) informs the patient 166 about relevant details of the process (e.g. not to talk to the examiner at any time) and (3) 167 guides the patient to the examination rooms after having him/her sign the written informed 168 consent form. The patient will then be placed on the treatment table as follows: 169
(1) Supine position. 170
Lower extremities undressed to the skin (all patients are asked to wear shorts). 171
Lower extremities pre-positioned by the study assistant as required for LAD 172
testing. 173
For LAD testing the knee is required to be aligned in 90° of flexion. This will be measured 174 using a standard goniometer. In order to achieve neutral tibial rotation the second metatarsal 175 will be aligned in the para-sagittal plane. In order to avoid any personal contact between the 176 
Testing procedure 181
Three different examiners (all of them licensed physical therapists) with varying professional 182 experience (1 year vs. 8 years vs. 30 years) will independently examine both knees of each 183 individual participant. Since we also report on intra-rater reliability, all patients will be tested 184 twice, once in a morning session and once in an afternoon session. All examiners will be 185 blinded to the respective participant's MRI scan, which has been evaluated prior to study 186 inclusion by an independent radiologist. As soon as the patient is placed properly, the first 187 examiner enters the room. Order of tester appearance will be randomized for both testing 188 sessions (morning and afternoon) using a random number table. 20 Additionally, the order of 189 patient appearance will be randomized for the afternoon session in order to avoid testers 190 recalling their first choices during the morning session. Upon entering the room, the first 191 examiner picks a slip of paper. The words LEFT KNEE or RIGHT KNEE will be written on 192 the backside of the paper. This guarantees that the knees of each patient will be examined 193 randomly. The independent study assistant will monitor this procedure. Subsequently, the 194 examiner will position himself in a sitting position on the patient's forefoot to gently fix it to 195 the treatment table. In order to accurately perform the LAD test, the examiner will place his 196 hands as follows: the lateral hand will be placed laterally onto the distal end of the femur 197 being careful not to deform the iliotibial band. The heel of the fully pronated medial hand will 198 be placed onto the posterior medial aspect of the proximal tibia. The forearm will be oriented 199 towards Gerdy's tubercle. The examiner's fingers encompass the anterior tibial border. After 200 correct hand positioning, the examiner pushes the tibia repeatedly in lateral-anterior direction 201 tester, the study assistant repositions the patient correctly. Without getting in contact with the 209 previous examiner, the second investigator enters the room and proceeds as described. 210
Following that, the third examiner will assess the patient. A new blank case report form will 211 be used for every tester and patient. Each tester will wait in a separate room to be picked up 212 by the study assistant. Raters are not allowed to use cell phones and computers during data 213 collection at any time. Any contact between testers is thus avoided. 214
215
Data analysis 216
Data analysis will be performed using IBM's Statistical Package for the Social Sciences 217 (SPSS, Version 24; IBM Corporation, Armonk, NY). Descriptive statistics will be obtained 218 for overall sample characterizations. Interval-scaled variables (e.g. height, weight, age) will 219 be shown as mean and standard deviation. Nominal data (e.g. sex) will be shown as percent 220 values. LAD test outcome criteria (positive vs. negative) will also be shown as percent 221 agreement (yes vs. no). In order to answer the main question of the present study, Fleiss' 222 kappa values will be calculated. To sort out whether there is a significant clinical agreement 223 of LAD test and MRI outcome, the sensitivity, specificity, positive and negative likelihood 224 ratio will be calculated and displayed in a 2x2 table. To clarify whether there is a correlation 225 between LAD test outcome and tester experience, sensitivity, specificity, positive and 226 negative likelihood ratios will be calculated for each tester separately. 227 
ETHICS AND DISSEMINATION 231
The study will be conducted in agreement with the 2013 World Medical Association 232
Declaration of Helsinki. 21 In accordance with these ethical principles, the review board of the 233 city of Vienna was informed about the study and asked for a written approval. Ethical 234 permission (EK16-081-0616) to conduct this study was granted on 1 September 2016. 235
Additionally, this study was registered in the German Trials Register (DKRS) under 236 DRKS00013268. Participation in the study will be voluntary. Signing a written informed 237 consent prior to testing will be mandatory for all study participants. Regarding personal data 238 and research data management, the Austrian Federal Data Protection Act will be respected. 239
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Methods and Analysis: Fifteen patients presenting with an MRI-confirmed acute or chronic 38
unilateral PCL rupture and 15 subjects with no prior knee injury in their medical history will 39 be included in this prospective single-blinded cross-sectional cohort study. Three examiners 40 with different lengths of working experience (range 1-30 years), blinded to MRI outcomes 41 and patient history, will use the LAD test on both knees of each participant to test for PCL 42 integrity. Examiners will independently document the PCL status of each knee on a blank 43 case report form. Fleiss-Kappa values will be calculated to investigate whether the LAD test 44
shows clinically significant inter-rater and intra-rater reliability. Furthermore, LAD test 45 outcomes will be compared with MRI, which serves as reference standard to check for 46 concurrent validity. Moreover, LAD test accuracy with respect to tester experience will be 47
evaluated. 48
Ethics and Dissemination: The study will be conducted in agreement with the World 49
Medical Association Declaration of Helsinki (2013). Ethical permission (EK16-081-0616) to 50
conduct this study was obtained from the review board of the City of Vienna on 1 September 51
All personal and research data will be used in accordance with the Austrian Federal 52
Data Protection Act and will be anonymized before publication in relevant international peer-53 reviewed journals. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 -The present study is adequately powered to detect clinically significant levels of LAD 66 test inter-and intra-rater reliability. 67 -This is the first study to provide sensitivity and specificity data as well as positive and 68 negative likelihood ratios of the LAD test. 69 -This is the first study to provide preliminary data on whether experience with the LAD 70 test influences concurrent validity. 71 -The study design takes account of measurement bias and ascertainment bias. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 testing procedures. This test examines the knee while positioned in 90° of flexion, with the 91 patient lying supine, so the PCL is aligned nearly perpendicular to the tibial plateau. 9 In this 92 knee position, the PCL is enabled to restrict lateral movement of the tibia versus the femur.
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With respect to the intercondylar eminence, the LAD testing force is applied from medial and 94 slightly posterior (also recognized as medial-posterior) to lateral and slightly anterior (also 95 recognized as lateral-anterior) in the direction of Gerdy's tubercle 7 (Figure 1) . 96
Both construct and concurrent validity of the LAD test as a valid measure for identifying PCL 97 integrity have recently been established in a cadaveric study. 7 However, whether the LAD test 98 indeed sufficiently detects PCL ruptures in vivo, and whether it shows clinically significant 99 levels of intra-and inter-rater reliability remains to be examined. Furthermore, concurrent 100 validity of the LAD test compared to magnetic resonance imaging (MRI) has not yet been 101 evaluated. Therefore, the main objective of the present study is to investigate if the LAD test 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Additionally, this study aims to evaluate the concurrent validity of the LAD test. Therefore, 104 test outcomes will be compared to MRI, which is considered the current reference standard in 105 PCL rupture diagnostics, because it shows high correlation with arthroscopic findings.
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Moreover, this study aims to investigate whether differences in LAD test accuracy are subject 107 to the investigator's experience with the LAD test. 108
109
METHODS AND ANALYSIS 110
Study design 111
This evaluation of validity and intra/inter-rater reliability is a prospective, single-112 blinded cross-sectional diagnostic phase II study. 113
114
Patient and Public Involvement 115
Patients and/or public were neither involved in the design of this study protocol nor in 116 the development of the research question. Patients and/or public will not be involved in the 117 recruitment process. Patient participation during data collection is described in detail in 118
sections Preparation procedure and Testing procedure of this study protocol. Participating 119 patients will be asked if they want to be informed about the study results. Those who indicate 120 interest will be send a result exposé edited in lay language. 121 122 Sample size calculation 123
Donner and Rotondi
19 supply the sample size requirements that achieve a pre-specified 124 expected lower limit for the 95% confidence interval about the intraclass kappa statistic κ for 125 the case of multiple raters and a binary outcome variable. Current epidemiological data on 126 PCL rupture suggest a prevalence of 4% to 40%. 20 Thus, an adequate estimated prevalence of 127 ruptured PCL in a diagnostic phase II study sample was expected to be 25%. Based on this 128 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
estimation and on a hypothesized lower limit for the 95% confidence interval of a kappa value 129 of 0.6, at least 55 knees need to be included in order to determine the presence of a clinically 130 significant inter-rater agreement. Therefore, 15 PCL-deficient knees and 45 healthy knees will 131 be included for testing, resulting in a total sample size of 30 subjects. Correspondingly, 15 132 patients presenting with an MRI confirmed acute or chronic unilateral PCL rupture and 15 133 subjects with no prior knee injury in their medical history will be included in the study. 134
135
Subject recruitment and inclusion and exclusion criteria 136
Patients will be recruited from the trauma hospital Unfallkrankenhaus Klagenfurt 137 (Austria) by one of the participating medical doctors according to pre-defined inclusion and 138 exclusion criteria. Eligible patients need to present with an acute or chronic unilateral PCL 139 rupture as confirmed by MRI scan interpreted by an independent radiologist prior to 140 inclusion. The healthy age-and gender-matched control group will be recruited from the staff 141 of the Speising Orthopaedic Hospital (Vienna, Austria). The complete study procedure is 142 depicted in Figure 2 and will be discussed in detail in the subsequent sections. In order to take 143 part in this study, participants must fulfill the following inclusion criteria: 144
(1) Age >18 years; 145 will not be excluded. Instead, the radiologist will document any concomitant knee injuries or 168 degenerative changes observed on the MRI, where special focus will be placed on coexistent 169 PLC and MCL injuries. 170
171
Preparation procedure 172
The names of eligible patients will be recorded on a recruiting list at the study center 173 at Unfallkrankenhaus Klagenfurt. Subsequently, those patients will be called by an 174 independent study assistant who will inform them about the study and ask if they are 175 interested to participate. Those interested will be marked on the list. At the end of patient 176 recruiting, the study assistant will enroll gender-and age-matched healthy subjects from the 177 staff of the Speising Orthopaedic Hospital in Vienna. The study assistant will schedule 178 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Lower extremities undressed to the skin (all patients are asked to wear shorts). 186
Lower extremities pre-positioned by the study assistant as required for LAD 187
testing. 188
For LAD testing the knee is required to be aligned in 90° of flexion. This will be 189 measured using a standard goniometer. In order to achieve neutral tibial rotation, the second 190 metatarsal will be aligned in the para-sagittal plane. In order to avoid any personal contact 191 between the examiner and the patient/subject, the participants will be hidden behind a curtain. 192
Only the participants' feet will be visible to the examiner. The study assistant will not play 193 any role in the judgment of either the index test or the reference test, nor in data analysis. 194
195
Testing procedure 196
Three different examiners (all of them licensed physical therapists) with varying 197 professional experience (1 year vs. 8 years vs. 30 years) will independently examine both 198 knees of each individual participant. Since we also report on intra-rater reliability, all patients 199 will be tested twice, once in a morning session and once in an afternoon session. All 200 examiners will be blinded to the respective participant's MRI scan, which has been evaluated 201 prior to study inclusion by an independent radiologist. As soon as the patient is placed 202 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 properly, the first examiner enters the room. Order of tester appearance will be randomized 203 for both testing sessions (morning and afternoon) using a random number table. 22 
204
Additionally, the order of patient appearance will be randomized for the afternoon session in 205 order to avoid testers recalling their first choices during the morning session. Upon entering 206 the room, the first examiner picks a slip of paper. The words LEFT KNEE or RIGHT KNEE 207 will be written on the backside of the paper. This guarantees that the knees of each patient 208 will be examined randomly. The independent study assistant will monitor this procedure. 209 Subsequently, the examiner will position himself in a sitting position on the patient's forefoot 210 to gently fix it to the treatment table. In order to accurately perform the LAD test, the 211 examiner will place his hands as follows: the lateral hand will be placed laterally onto the 212 distal end of the femur being careful not to deform the iliotibial band. The heel of the fully 213 pronated medial hand will be placed onto the posterior medial aspect of the proximal tibia. 214
The forearm will be oriented towards Gerdy's tubercle. The examiner's fingers encompass the 215 anterior tibial border. After correct hand positioning, the examiner pushes the tibia repeatedly 216 in lateral-anterior direction and pulls it back again in medial-posterior direction in order to 217 move through the entire range of motion. After doing so for ten repetitions, the examiner 218 notices the amount of lateral-anterior motion. Next, the examiner changes to the other side to 219 perform the LAD test in the same way. Having the direct side-to-side comparison, the tester 220 determines the knee presenting with a PCL rupture by marking one of the following 221 categories on a standardized case report form: (1) right PCL intact or right PCL ruptured and 222 (2) left PCL intact or left PCL ruptured. Subsequently, the examiner leaves the room. Prior to 223 the arrival of the next tester, the study assistant repositions the patient correctly. Without 224 getting in contact with the previous examiner, the second investigator enters the room and 225 proceeds as described. Following that, the third examiner will assess the patient. A new blank 226 case report form will be used for every tester and patient. Each tester will wait in a separate 227 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
ETHICS AND DISSEMINATION 246
The study will be conducted in agreement with the 2013 World Medical Association 247 Declaration of Helsinki. 23 In accordance with these ethical principles, the review board of the 248 city of Vienna was informed about the study and asked for a written approval. Ethical 249 permission (EK16-081-0616) to conduct this study was granted on 1 September 2016. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 11 consent prior to testing will be mandatory for all study participants. Regarding personal data 253 and research data management, the Austrian Federal Data Protection Act will be respected. 254
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